Talk:Indatuximab ravtansine
Jump to navigation
Jump to search
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: |
||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Indatuximab ravtansine.
|
All genetic types of MMÂ ?
multiple myeloma says
"A chromosomal translocation between the immunoglobulin heavy chain gene (on chromosome 14, locus q32) and an oncogene (often 11q13, 4p16.3, 6p21, 16q23 and 20q11[17]) is frequently observed in patients with multiple myeloma. This mutation results in dysregulation of the oncogene which is thought to be an important initiating event in the pathogenesis of myeloma.[citation needed] The result is proliferation of a plasma cell clone and genomic instability that leads to further mutations and translocations. The chromosome 14 abnormality is observed in about 50% of all cases of myeloma. Deletion of (parts of) chromosome 13 is also observed in about 50% of cases."
Its not clear if/how the chromosome changes relate to overexpression of CD138 that this drug targets. - Rod57 (talk) 00:57, 2 February 2016 (UTC)